AXSM News and Press, Axsome Therapeutics Inc. From 05/13/23

2023-05-13 08:00:00 ET The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. But history has demonstrated time and again that a buy-and-hold strategy is one of the best ways for the average person to generate wealth. So it pays to target s...

2023-05-11 16:18:07 ET Summary BioXcel Therapeutics, Inc. is currently in exciting times, awaiting very important clinical trial results in the coming weeks. The recently released BioXcel Therapeutics first-quarter results provided a low revenue figure for IGALMI, however, the mar...

2023-05-09 15:37:01 ET Axsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two products: Sunosi, a sleep disorder drug it acquired from Jazz Pharmaceuticals ; and Auvelity, an antidepressant it developed in house. Thanks to those successes...

2023-05-09 14:17:57 ET Summary Axsome reported its Q1'23 earnings yesterday - net loss was $(0.26) per share. The company's 2 commercial products - newly approved Auvelity and Sunosi, acquired from Jazz Pharmaceuticals earned $29m. Axsome smashed analysts' estimates thanks to ...

2023-05-08 14:22:05 ET Axsome Therapeutics, Inc. (AXSM) Q1 2023 Earnings Conference Call May 8, 2023 08:00 ET Company Participants Mark Jacobson - Investor Relations Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Lori Englebe...

2023-05-08 14:00:35 ET Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM) Q1 2023 Earnings Call May 08, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Axsome Therapeutics (AXSM) Q1 2023 Earnings Call...

2023-05-08 09:28:58 ET Axsome Therapeutics ( NASDAQ: AXSM ) added ~6% pre-market after its Q1 2023 results as investors turned attention to sales of its newly approved depression therapy, Auvelity, during its first full quarter of commercial launch. In October, Axsome ( AX...

2023-05-08 07:03:54 ET Axsome Therapeutics press release ( NASDAQ: AXSM ): Q1 EPS of -$0.26 may not be comparable to consensus of -$1.29. Revenue of $94.6M beats by $69.12M . Auvelity 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net prod...

Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi ® ex-U.S. license agreement upfront payment Company to host conference call tod...

2023-05-05 12:17:49 ET Axsome Therapeutics ( NASDAQ: AXSM ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is -$1.13 (-9.7% Y/Y) and the consensus Revenue Estimate is $25.48M Over the last 1 year, AXSM ...